桂龙咳喘宁品牌怎么样 申请店铺

我要投票 桂龙咳喘宁在医疗器械行业中的票数:615 更新时间:2025-12-04
桂龙咳喘宁是哪个国家的品牌?「桂龙咳喘宁」是桂龙药业(安徽)有限公司旗下著名品牌。该品牌发源于安徽省马鞍山市,由创始人Stephen John Coplin在2003-11-25期间创立,经过多年的不懈努力和高速发展,现已成为行业的标杆品牌。

外推网助力桂龙咳喘宁品牌出海!将品牌入驻外推网,定制桂龙咳喘宁品牌推广信息,可以显著提高桂龙咳喘宁产品曝光,简直是跨境电商爆单神器!目前仅需1000元/年哦~

桂龙咳喘宁怎么样

桂龙咳喘宁,知名咳嗽药品牌,成立于1989年,高新技术企业,中药呼吸系统和咽喉品类领域领先企业,集研发/生产/销售于一体的中药企业


桂龙药业成立于1989年,是集研发、生产、销售为一体的中药行业企业。桂龙,取自谐音“贵”“隆”,意为富贵华荣兴旺发达。且“桂”,有桂树四季翠绿,香飘万里而古朴典雅,是传统中药的化身;“龙”,象征着东方文化与蓄势勃发的力量。

公司拥有员工约1000人,总部位于福建省厦门市,在安徽省马鞍山市和山西省忻州市设有两个生产基地,总占地面积11万平方米,建筑面积近4万平方米,均为现代化的花园式GMP工厂。 桂龙药业在全国设立27个销售办事处,拥有500人的销售团队,销售人员有效管理近6万家零售终端门店,产品覆盖全国近三十万家零售药店,以及全国所有主流连锁药店。

2003年经当涂县委、县人大招商引资在当涂经济开发区征地120亩,投资5000万元,建立了一座符合GMP要求的生产企业——桂龙药业(安徽)有限公司。公司目前拥有国药准字号品种31个,主要生产经营范围为:片剂、胶囊剂、颗粒剂、煎膏剂、及生产加工、经营糖果。其主导产品主要有:慢严舒柠牌清喉利咽颗粒、桂龙咳喘宁胶囊、新生化颗粒、复方柴胡安神颗粒、好爽糖等。科技创新、管理创新、岗位创新、市场创新是企业发展的原动力。科技人员占员工比例36%以上。公司拥有的技术研发中心和检测中心,保障了公司科技的可持续发展,保障了药品的质量和药品的安全。

桂龙专注于中药呼吸系统和咽喉品类领域,创立了国内呼吸系统和咽喉领域两个品牌“桂龙”牌、“慢严舒柠”牌。

“有健康就有桂龙,桂龙药业、健康事业”是桂龙药业的宗旨;品牌战略、人才战略、创新战略是桂龙发展的三个支撑;“敬业”、“诚信”、“责任”、“创新”是桂龙发展的核心理念。随着企业的发展壮大,桂龙药业现有的生产与研发平台不足以支撑桂龙药业未来若干年的迅速持续发展,为此桂龙药业决定在当涂经开区征地数百亩,以国内专业的制药技术和工艺装备,打造一个集生物医药生产和研究开发于一体的现代化医药产业园,以此支撑桂龙未来十多年的长足发展和技术创新、科技进步。


Guilong Kechuanning, a famous cough medicine brand, was founded in 1989. It is a high-tech enterprise, a leading enterprise in the field of traditional Chinese medicine respiratory system and throat category. Guilong pharmaceutical, a traditional Chinese medicine enterprise integrating R & D, production and sales, was founded in 1989. It is a traditional Chinese Medicine enterprise integrating R & D, production and sales. Guilong, from the homonym "Gui" and "long", means prosperity and prosperity. And "Gui" is the embodiment of traditional Chinese medicine, which has four seasons of green, fragrant and elegant, and "long" symbolizes the power of Oriental culture and vigorous development. The company has about 1000 employees and its headquarter is located in Xiamen City, Fujian Province. It has two production bases in Maanshan City, Anhui Province and Xinzhou City, Shanxi Province, covering a total area of 110000 square meters and a building area of nearly 40000 square meters, all of which are modern garden GMP factories. Guilong pharmaceutical has 27 sales offices in China, with a sales team of 500 people. The sales staff effectively manage nearly 60000 retail terminal stores, covering nearly 300000 retail pharmacies and all mainstream chain pharmacies in China. In 2003, Dangtu County Party committee and County People's Congress invested 120 mu of land in Dangtu economic development zone and invested 50 million yuan to establish a GMP compliant production enterprise - Guilong Pharmaceutical (Anhui) Co., Ltd. At present, the company has 31 varieties of State Pharmaceutical quasi brand, the main production and business scope are: tablets, capsules, granules, decoctions, as well as the production, processing and operation of candy. Its main products are: Manyan shuning brand Qinghou Liyan granules, Guilong Kechuanning capsule, xinbiochemical granules, compound Bupleurum Anshen granules, haoshuangtang, etc. Technological innovation, management innovation, post innovation and market innovation are the driving force of enterprise development. Science and technology personnel account for more than 36% of employees. The technology R & D center and testing center of the company ensure the sustainable development of the company's science and technology and the quality and safety of drugs. Focusing on the field of respiratory system and throat category of traditional Chinese medicine, Guilong has established two domestic brands in the field of respiratory system and throat, "Guilong" brand and "slow, strict, shuning" brand. The aim of Guilong pharmaceutical industry is to "have health, Guilong pharmaceutical industry and health cause"; brand strategy, talent strategy and innovation strategy are the three supports for the development of Guilong; dedication, integrity, responsibility and innovation are the core concepts for the development of Guilong. With the development of enterprises, the existing production and R & D platform of Guilong pharmaceutical industry is not enough to support the rapid and sustainable development of Guilong pharmaceutical industry in the next few years. Therefore, Guilong pharmaceutical industry decided to take hundreds of mu of land in Dangtu Economic Development Zone to build a modern pharmaceutical industrial park integrating biological pharmaceutical production and research and development with domestic professional pharmaceutical technology and process equipment, so as to support Guilong pharmaceutical industry Long's considerable development and technological innovation and scientific and technological progress in the next ten years.

本文链接: https://brand.waitui.com/0d765d197.html 联系电话:请联系客服添加 联系邮箱:请联系客服添加

外推网广告位招租,每天只要9块9

7×24h 快讯

中国游客冬季出游为西班牙旅游业拓展新增长

随着冬季到访西班牙的中国游客不断增加,西班牙旅游业人士指出,中国游客“反季节出行”为西班牙旅游业打开新的增长空间。西班牙观光委员会副主席圣地亚哥·巴列霍日前在接受记者采访时介绍,中国游客对冬游西班牙的兴趣在增加。2025年冬至2026年春,两国间直航航班密度将达到历史最高水平,每周直航班次较2019年几乎翻倍。“在旅游行业,直航是关键。航线越多,旅游增长越快,且二者互为因果。”(新华社)

25分钟前

摩根士丹利:明年底沪深300指数目标4840点

摩根士丹利2日举办线下媒体圆桌分享会,摩根士丹利中国首席经济学家邢自强和摩根士丹利中国首席股票策略师王滢讨论了2026年中国经济和股市策略。摩根士丹利表示,随着市场对美元资产“一枝独秀论”祛魅,全球资金对中国资产配置兴趣回升,中国股市重新被定义为“有成长性的市场”。该机构小幅上调了中国股票指数目标,将2026年12月沪深300指数的目标点位定为4840点,并表示“明晟中国指数12个月前瞻市盈率在12至13倍之间是合理的”。 (上证报)

25分钟前

美股大型科技股盘前多数上涨,英伟达涨超1%

36氪获悉,美股大型科技股盘前多数上涨,截至发稿,英伟达涨超1%,亚马逊涨0.52%,特斯拉涨0.32%,谷歌涨0.29%,Meta涨0.19%,苹果涨0.07%,奈飞跌超1%,微软跌0.07%。

25分钟前

热门中概股美股盘前普跌,哔哩哔哩跌超2%

36氪获悉,热门中概股美股盘前普跌,截至发稿,哔哩哔哩跌超2%,阿里巴巴、京东跌超1%,百度跌0.82%,拼多多跌0.71%,网易跌0.67%,小鹏汽车跌0.56%,蔚来跌0.2%,理想汽车涨0.55%。

25分钟前

印度卢比对美元汇率跌至历史新低

印度卢比对美元汇率3日首次跌破90卢比兑换1美元关口,创历史新低。当天,受卢比大幅贬值影响,印度主要股指Nifty 50指数跌破26000点,孟买证券交易所敏感指数早盘交易下跌近200点。一些市场分析人士认为,印度和美国贸易谈判的不确定性是卢比汇率承压的重要原因。美国对印度产品征收的关税税率累计高达50%,而双方贸易谈判进展缓慢。此外,印度央行未采取措施维持汇率,加剧了市场对卢比贬值的担忧。(新华社)

25分钟前

本页详细列出关于桂龙咳喘宁的品牌信息,含品牌所属公司介绍,桂龙咳喘宁所处行业的品牌地位及优势。
咨询